United States
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing innovative medicines for a wide range of diseases.
Key Products
- EYLEA Injection: Treats wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
- Dupixent Injection: Used for atopic dermatitis and asthma in adults and pediatric patients.
- Libtayo Injection: Targets metastatic or locally advanced cutaneous squamous cell carcinoma.
- Praluent Injection: For heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults.
- REGEN-COV: A treatment for COVID-19.
- Kevzara Solution: Addresses rheumatoid arthritis in adults.
- Inmazeb Injection: Treats infections caused by Zaire ebolavirus.
- ARCALYST Injection: For cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome.
- ZALTRAP Injection: Used intravenously for metastatic colorectal cancer.
- Evkeeza: A treatment for HoFH.
- Ordspono: For follicular lymphoma and diffuse large B-cell lymphoma.
- Veopoz: Targets CD55-deficient protein-losing enteropathy.
Research & Development
Regeneron is actively developing product candidates for eye diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain, and hematologic conditions.
Collaborations
- Partnered with Mammoth Biosciences, Inc. to research, develop, and commercialize in vivo CRISPR-based gene editing therapies.
- Collaborating with Sonoma Biotherapeutics, Inc. to discover and develop engineered regulatory T cell therapies.
Company Background
Founded in 1988, Regeneron is headquartered in Tarrytown, New York.
